Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Metformin + nivolumab is a combination therapy that pairs the oral antidiabetic drug metformin with the immune checkpoint inhibitor nivolumab. This combination has been investigated for potential synergistic antitumor effects. Nivolumab is a programmed death-1 (PD-1) inhibitor that works by blocking the PD-1 receptor, enhancing T-cell immune responses against cancer cells. Metformin, traditionally used for diabetes management, has shown potential to elicit metabolic changes that favor decreased intratumoral oxygen consumption and may improve the efficacy of immunotherapy. The combination has been studied in various cancer types including microsatellite stable (MSS) metastatic colorectal cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and pancreatic cancer.
- Brand names
- OpdivoGlucophage
- Other names
- nivolumab + metforminnivolumab + metformin hydrochloride combinationanti-PD-1 antibody + metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on metformin + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + nivolumab.